University of Washington
Seattle, Washington, 98195, United States
NCT Number: NCT00842751
The purpose of this study is to test how the body absorbs and processes new forms of oral testosterone. Information gained during the study may help develop better forms of testosterone therapy in the future.
Looking for future studies?
Notify Me18 year–50 year
Male
Interventional
Phase 2
Seattle, Washington, 98195, United States
We will be using three drugs: The first, acyline, temporarily turns off the body's production of testosterone for about two weeks. Subjects will receive acyline as shots three times over a six-week drug administration period. During the time when the body's production of testosterone is turned off, we will give testosterone either by itself or with a medication called finasteride by mouth twice daily for one week to see how much is absorbed and present in the bloodstream after administration. Subjects will go through three one-week study drug exposure periods. During two of the three one-week study drug administration periods subjects will also take a second medication, finasteride, by mouth twice daily. On the last day of each one-week drug administration period, subjects will be admitted to the University of Washington General Clinical Research Center overnight for monitoring of your blood testosterone levels. There will be 3 overnight visits for this study. This study will allow us to determine the absorption of testosterone taken by mouth, and the relative impact of two different doses of oral finasteride on testosterone absorption.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Acyline 300mcg/kg subcutaneous (days 1, 15 & 29) + testosterone undecanoate 200 mg, twice daily orally + finasteride placebo
Other names: propecia
Washout of 7 days between each of the 3 treatment arms
Other names: no active drugs
Acyline 300mcg/kg subcutaneous + testosterone undecanoate 200 mg, twice daily orally + finasteride 0.5mg twice daily, orally
Other names: propecia
Acyline 300mcg/kg subcutaneous + testosterone undecanoate 200 mg, twice daily orally + finasteride 1mg twice daily, orally
Other names: propecia
Washout of 7 days between each of the 3 treatment arms
Other names: no active drug
Time frame: 0,1,2,4,8,and 12-hour post dose
Area under the curve of serum testosterone Pharmacokinetic measures time-weighted mean concentration calculated as area under the concentration curve (AUC) divided by time from initiation of dosing for the morning dose and corrected for differences in baseline hormone concentration.
Time frame: 0,1,2,4,8,and 12-hour post dose
Area under the curve of serum dihydrotestosterone
Time frame: 0,1,2,4,8,and 12-hour post dose
Area under the curve of serum estradiol
University of Washington
Other
Pharmacokinetics of a Novel Oral Testosterone Undecanoate Formulation With Concomitant Inhibition of 5alpha-Reductase by Finasteride
Acronym: Oral T7
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06834295
Healthy Males
Nottingham, UK, United Kingdom
View Trial DetailsNCT01367561
Healthy Males
Tarrytown, New York, United States
View Trial DetailsNCT05294198
Healthy Males
Petrolina, Pernambuco, Brazil
View Trial DetailsNCT05277597
Behavior, Healthy Males
Nowy Sącz, Poland
View Trial Details